A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer
7 Hills Pharma, LLC
Intensity Therapeutics, Inc.
Bristol-Myers Squibb
Xencor, Inc.
Bristol-Myers Squibb